The clinical severity of multiple sclerosis (MS), an autoimmune disorder of the central nervous system, is thought to be determined by environmental and genetic factors. In their genome wide association study (GWAS), Harroud et al.1 identified a single nucleotide polymorphism (SNP), rs10191329, which is associated with MS severity in two large independent cohorts of MS patients. Different approaches were followed by the authors to prioritize the targeted genes which are transcriptionally regulated by such a SNP. It was concluded that the identified SNP regulate a group of proximal genes involved in brain resilience and cognitive abilities rather than immunity. Here, by conducting an alternative strategy for gene prioritization, we reached the opposite conclusion. According to our re-analysis, the main target of rs10191329 is N-Acetylglucosamine Kinase (NAGK), a metabolic gene recently shown to exert major immune functions.